Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb;200(3):275-276.
doi: 10.1111/bjh.18524. Epub 2022 Nov 21.

Why should intramuscular anti-D be different from intravenous anti-D?

James B Bussel  1
Affiliations
Comment

Why should intramuscular anti-D be different from intravenous anti-D?

James B Bussel. Br J Haematol. 2023 Feb.

Abstract

For reasons of safety the use of intravenous anti D to treat ITP has largely been abandoned because of the risk it incurs of intravascular haemolysis. Intramuscular delivery of anti-D could be a safer approach and deserves to be further evaluated. IV anti-D was a mainstay of ITP treatment in the United States in the 1990's until the development of intravascular hemolysis (IVH) and its serious even fatal consequences was appreciated. Subsequently, treatment of patients with ITP with IV anti-D has become very rare given other alternatives and the IVH risk. IM anti-D does not carry a risk for IVH and it should be re-evaluated and reconsidered as an option for D+ DAT-negative not splenectomized adults who do not have a long duration of ITP and require maintenance treatment. Commentary on: Lakhwani, et al. Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience. Br J Haematol 2023;200:353-357.

Keywords: ITP; intravascular hemolysis; subscutaneous.

PubMed Disclaimer

Comment in

Comment on

Similar articles

See all similar articles

References

REFERENCES

    1. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106(5):1532-7.
    1. Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino MD, et al. Anti-D immune globulin for the treatment of immune thrombocytopenia: consensus and controversy. Transfusion. 2012;52(5):1126-36.
    1. Romano EL, Hughes-Jones NC, Mollison PL. Direct antiglobulin reaction in ABO-haemolytic disease of the newborn. BMJ. 1973;1(5852):524-6.
    1. Lakkaraja M, Jin JC, Manotas KC, Vinograd CA, Ferd P, Gabor J, et al. Blood group a mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. Transfusion. 2016;56(10):2449-54. https://doi.org/10.1111/trf.13779
    1. Cooper N, Heddle N, de Haas M, Reid M, Lesser M, Fleit H, et al. IV anti-D and IVIG achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol. 2004;124(4):511-8.

LinkOut - more resources